New Published Data Demonstrate Endocyte, Inc.'s Targeted Small Molecule Drug Conjugate Approach Shows Promising Results in Polycystic Kidney Disease Model

Published: Aug 03, 2012

WEST LAFAYETTE, Ind., Aug. 3, 2012 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced that Endocyte's approach of utilizing a SMDC targeted to the folate receptor (FR) may provide a promising treatment for patients with autosomal-dominant polycystic kidney disease (ADPKD). In a mouse model of polycystic kidney disease (PKD), treatment with a folate-conjugated form of rapamycin, FC-rapa, (EC0371) strongly attenuated proliferation and growth of renal cysts and preserved renal function. The results were published online ahead of print in the Journal of the American Society of Nephrology and will be available in print in the October issue.

Back to news